The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

de Gregorio, Amelie; Janni, Wolfgang; Friedl, Thomas W. P.; Nitz, Ulrike; Rack, Brigitte; Schneeweiss, Andreas; Kates, Ronald; Fehm, Tanja; Kreipe, Hans; Christgen, Matthias; Kuemmel, Sherko; Trapp, Elisabeth; Wuerstlein, Rachel; Haertkopf, Andreas; Clemens, Michael; Reimer, Toralf; Haeberle, Lothar; Fasching, Peter A.; Gluz, Oleg; Harbeck, Nadia

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

Autor(en):

de Gregorio, Amelie; Janni, Wolfgang; Friedl, Thomas W. P.; Nitz, Ulrike; Rack, Brigitte; Schneeweiss, Andreas; Kates, Ronald; Fehm, Tanja; Kreipe, Hans; Christgen, Matthias; Kuemmel, Sherko; Trapp, Elisabeth; Wuerstlein, Rachel; Haertkopf, Andreas; Clemens, Michael; Reimer, Toralf; Haeberle, Lothar; Fasching, Peter A.; Gluz, Oleg; Harbeck, Nadia

Tübinger Autor(en):

Hartkopf, Andreas

Erschienen in:

British Journal of Cancer (2022), Bd. 126, H. 12, S. 1715-1724

Verlagsangabe:

Springernature

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1038/s41416-021-01690-6

ISSN:

0007-0920